The PrIMAVeRa project, a public-private partnership supported by the European Federation of Pharmaceutical Industries and Associations (EFPIA), focuses on demonstrating vaccines' role in reducing antimicrobial resistance (AMR). On October 23, 2024, Vaccines Europe, a specialised vaccine group within the EFPIA, hosted a strategic meeting in Brussels focusing on the role of vaccines in combating AMR.
October 2024
At this meeting, PrIMAVeRa Coordinator Dr. Irina Meln and PrIMAVeRa EFPIA lead Dr. Venanzio Vella presented updates on activities and outcomes within PrIMAVeRa highlighting significant challenges in accessing diverse databases. A systematic review conducted by PrIMAVeRa revealed that European data on AMR burden for specific pathogen-infection combinations is both limited and often associated with a high risk of bias. This gap includes a lack of disaggregated data by key demographics (age, sex, and comorbidity), as well as insufficient data on the health and economic burden of AMR for most pathogens and infection types.
Reliable data on incidence and health and economic outcomes for several pathogen-infections disaggregated by age, sex and comorbidity is essential for generating accurate predictions from models like those being developed within PrIMAVeRa to evaluate the impact of vaccines and monoclonal antibodies on AMR. Research priorities need to be established to address these gaps and to guide future health technologies and strategies aimed at reducing the burden of AMR in Europe. Aligning institutions and organizations across sectors is critical to achieving these goals, which could yield data-driven policy recommendations to combat AMR effectively.
The PrIMAVeRa project team is grateful to the Vaccines Europe team for this opportunity to discuss key challenges and look forward to continued exchange to improve global health.
For more information, please visit the PrIMAVeRa project website (www.primavera-amr.eu) and access the project resources hosted by the ECRAID-Base EPI-Net (https://epi-net.eu/primavera/about/).
Media Contact:
Romina Di Marzo
Senior Communications and Advocacy Manager
Irina Meln
Project Leader
This work has received support from the IMI2/EU/EFPIA Joint Undertaking Inno4Vac grant n° 101034420 [PrIMAVeRa]. This reflects the author's view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use made of the information contained therein.
Comments